Induced osteoclastogenesis by fluoroquinolones in unstimulated and stimulated human osteoclast precursor cells

Bone

Volumn 51, Issue 1, 2012, Pages 17-27

  Costa Rodrigues, J ^a   Martins, E G ^a   Fernandes, M H ^a  

^a Universidade do Porto   (Portugal)

Author keywords

Bone metabolism; Fluoroquinolones; Human osteoclast precursor cells; M CSF and RANKL; Osteoclastogenesis

Indexed keywords

ACTIN; CALCITONIN RECEPTOR; CALCIUM PHOSPHATE; CELL ENZYME; CIPROFLOXACIN; COLONY STIMULATING FACTOR 1; LEVOFLOXACIN; MITOGEN ACTIVATED PROTEIN KINASE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; PROTEIN TRAP; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VITRONECTIN;

ADULT; APOPTOSIS; ARTICLE; BONE METABOLISM; CELL MATURATION; CELL MEMBRANE POTENTIAL; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; M CSF GENE; MALE; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RANKL GENE; STEM CELL;

ACID PHOSPHATASE; ADULT; APOPTOSIS; CELLS, CULTURED; FLUOROQUINOLONES; HUMANS; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICROSCOPY, CONFOCAL; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS;

EID: 84860111064     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.03.015     Document Type: Article

References (52)

1. Dan M., Golomb J., Gorea A., Braf Z., Berger S.A. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother 1986, 30:88-89.
2. Esposito S., Noviello S., D'Errico G., Motta G., Passali D., Aimoni C., et al. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. J Antimicrob Chemother 2006, 57:789-792.
3. Fabre D., Bressolle F., Gomeni R., Arich C., Lemesle F., Beziau H., et al. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991, 35:2521-2525.
4. Gotfried M.H., Danziger L.H., Rodvold K.A. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001, 119:1114-1122.
5. Immanuel C., Hemanthkumar A.K., Gurumurthy P., Venkatesan P. Dose related pharmacokinetics of ofloxacin in healthy volunteers. Int J Tuberc Lung Dis 2002, 6:1017-1022.
6. Khan M.K., Khan M.F. Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. Pak J Pharm Sci 2008, 21:299-306.
7. MacGowan A.P., Greig M.A., Clarke E.A., White L.O., Reeves D.S. The pharmacokinetics of norfloxacin in the aged. J Antimicrob Chemother 1988, 22:721-727.
8. Parpia S.H., Nix D.E., Hejmanowski L.G., Goldstein H.R., Wilton J.H., Schentag J.J. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989, 33:99-102.
9. Swoboda S., Oberdorfer K., Klee F., Hoppe-Tichy T., von Baum H., Geiss H.K. Tissue and serum concentrations of levofloxacin 500mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery. J Antimicrob Chemother 2003, 51:459-462.
10. Wagenlehner F.M., Kees F., Weidner W., Wagenlehner C., Naber K.G. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400mg to healthy volunteers. Int J Antimicrob Agents 2008, 31:21-26.
11. Zulfiqar ul H., Riffa S., Naseer R. Gender differences on bioavailability of ofloxacin. J Ayub Med Coll Abbottabad 2008, 20:114-117.
12. Oliphant C.M., Green G.M. Quinolones: a comprehensive review. Am Fam Physician 2002, 65:455-464.
13. Sharma P.C., Jain A., Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 2009, 66:587-604.
14. Maxwell A. The molecular basis of quinolone action. J Antimicrob Chemother 1992, 30:409-414.
15. Blondeau J.M. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 2004, 49(Suppl. 2):S73-S78.
16. Teupe C., Meffert R., Winckler S., Ritzerfeld W., Tormala P., Brug E. Ciprofloxacin-impregnated poly-l-lactic acid drug carrier. New aspects of a resorbable drug delivery system in local antimicrobial treatment of bone infections. Arch Orthop Trauma Surg 1992, 112:33-35.
17. Kimura S., Toda H., Shimabukuro Y., Kitamura M., Fujimoto N., Miki Y., et al. Topical chemotherapy in human periodontitis using a new controlled-release insert containing ofloxacin. I. Microbiological observation. J Periodontal Res 1991, 26:33-41.
18. Sendzik J., Lode H., Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009, 33:194-200.
19. Huddleston P.M., Steckelberg J.M., Hanssen A.D., Rouse M.S., Bolander M.E., Patel R. Ciprofloxacin inhibition of experimental fracture healing. J Bone Joint Surg Am 2000, 82:161-173.
20. Tuncay I., Ozbek H., Kosem M., Unal O. A comparison of effects of fluoroquinolones on fracture healing (an experimental study in rats). Ulus Travma Acil Cerrahi Derg 2005, 11:17-22.
21. Perry A.C., Prpa B., Rouse M.S., Piper K.E., Hanssen A.D., Steckelberg J.M., et al. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clin Orthop Relat Res 2003, 95-100.
22. Datta H.K., Ng W.F., Walker J.A., Tuck S.P., Varanasi S.S. The cell biology of bone metabolism. J Clin Pathol 2008, 61:577-587.
23. Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007, 13:791-801.
24. Holtom P.D., Pavkovic S.A., Bravos P.D., Patzakis M.J., Shepherd L.E., Frenkel B. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J Orthop Res 2000, 18:721-727.
25. Miclau T., Edin M.L., Lester G.E., Lindsey R.W., Dahners L.E. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 1998, 16:509-512.
26. Rathbone C.R., Cross J.D., Brown K.V., Murray C.K., Wenke J.C. Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J Orthop Res 2011, 29:1070-1074.
27. Duewelhenke N., Krut O., Eysel P. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents Chemother 2007, 51:54-63.
28. Anan H., Matsumoto A., Hamachi T., Yoshimine Y., Morita Y., Maeda K. Effects of a combination of an antibacterial agent (ofloxacin) and a collagenase inhibitor (FN-439) on the healing of rat periapical lesions. J Endod 1996, 22:668-673.
29. Fukuishi N., Matsui N., Kanoh R., Akagi M. Novel action of quinolones on osteoclast-like cells. J Toxicol Sci 1999, 24:383-391.
30. Ostrov D.A., Magis A.T., Wronski T.J., Chan E.K., Toro E.J., Donatelli R.E., et al. Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening. J Med Chem 2009, 52:5144-5151.
31. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
32. - cell fractions. Cell Prolif 2011, 44:410-419.
33. Costa-Rodrigues J., Moniz K.A., Teixeira M.R., Fernandes M.H. Variability of the paracrine-induced osteoclastogenesis by human breast cancer cell lines. J Cell Biochem 2012, 113:1069-1079.
34. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
35. Costa-Rodrigues J., Fernandes M.H. Paracrine-mediated differentiation and activation of human haematopoietic osteoclast precursor cells by skin and gingival fibroblasts. Cell Prolif 2011, 44:264-273.
36. Zhao Q., Shao J., Chen W., Li Y.P. Osteoclast differentiation and gene regulation. Front Biosci 2007, 12:2519-2529.
37. Hotokezaka H., Sakai E., Kanaoka K., Saito K., Matsuo K., Kitaura H., et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002, 277:47366-47372.
38. Hotokezaka H., Sakai E., Ohara N., Hotokezaka Y., Gonzales C., Matsuo K., et al. Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J Cell Biochem 2007, 101:122-134.
39. Yamashita M., Otsuka F., Mukai T., Yamanaka R., Otani H., Matsumoto Y., et al. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regul Pept 2010, 162:99-108.
40. Costa-Rodrigues J., Fernandes A., Fernandes M.H. Reciprocal osteoblastic and osteoclastic modulation in co-cultured MG63 osteosarcoma cells and human osteoclast precursors. J Cell Biochem 2011, 112:3704-3713.
41. Costa-Rodrigues J., Teixeira C.A., Fernandes M.H. Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important?. Clin Exp Metastasis 2011, 28:505-514.
42. Kim H.J., Lee Y., Chang E.J., Kim H.M., Hong S.P., Lee Z.H., et al. Suppression of osteoclastogenesis by N, N-dimethyl-d-erythro-sphingosine: a sphingosine kinase inhibition-independent action. Mol Pharmacol 2007, 72:418-428.
43. Yang Q., McHugh K.P., Patntirapong S., Gu X., Wunderlich L., Hauschka P.V. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 2008, 27:589-599.
44. Hall T.J., Schaeublin M., Jeker H., Fuller K., Chambers T.J. The role of reactive oxygen intermediates in osteoclastic bone resorption. Biochem Biophys Res Commun 1995, 207:280-287.
45. Kawashima M., Fujikawa Y., Itonaga I., Takita C., Tsumura H. The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Mod Rheumatol 2009, 19:192-198.
46. Kellinsalmi M., Parikka V., Risteli J., Hentunen T., Leskela H.V., Lehtonen S., et al. Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro. Eur J Pharmacol 2007, 572:102-110.
47. Woo K.M., Kim H.M., Ko J.S. Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med 2002, 34:340-346.
48. Costa-Rodrigues J., Teixeira C.A., Sampaio P., Fernandes M.H. Characterisation of the osteoclastogenic potential of human osteoblastic and fibroblastic conditioned media. J Cell Biochem 2010, 109:205-216.
49. Mondal E.R., Das S.K., Mukherjee P. Comparative evaluation of anti-proliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac J Cancer Prev 2004, 5:196-204.
50. Sendzik J., Shakibaei M., Schafer-Korting M., Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signaling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 2005, 212:24-36.
51. Ostrov D.A., Magis A.T., Wronski T.J., Chan W.K.L., Toro E., Donatelli R.E., et al. Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening. J Med Chem 2009, 52:5144-5151.
52. Shan G., Li Y., Zhang J., Li W., Szulwach K.E., Duan R., et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008, 26:933-940.